How much does a box of olaparib targeted medicine cost?

Olaparib is a targeted drug mainly used to treat cancer patients carrying BRCA1 or BRCA2 gene mutations, especially ovarian cancer, breast cancer, pancreatic cancer and prostate cancer. Mutations in these genes will affect the DNA repair process, causing cells to accumulate more genetic damage, which may ultimately lead to cancer. Lynparza works by targeting a protein in cancer cells called PARP (poly ADP-ribose polymerase), which is involved in a key process of DNA repair.

Olaparib is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically. Specifications 150mg*56 tablets are priced at about four to five thousand yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper ones abroad are mainly generic drugs, mainly from Bangladesh and Laos. The price of 150mg*120 tablets is about 2,000 yuan, which is much cheaper than domestic drugs, and the ingredients are basically the same as the domestic original drugs.

PARPis expressed in both normal cells and cancer cells, but its importance is particularly prominent in cells with BRCA gene mutations. When the BRCA gene is damaged, cells become more dependent on PARP because they lack another pathway to repair DNA double-strand breaks. By inhibiting PARP, olaparib further weakens the repair ability of these cancer cells, resulting in DNA damage that cannot be repaired, thus triggering cell death. This mechanism is called "Synthetic lethality", which selectively kills tumor cells by interfering with the repair pathways of cancer cells, while having less impact on normal cells.

Olaparib was first approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of patients with advanced ovarian cancer, especially those with ovarian cancerBRCAPatients with mutations who are sensitive to platinum drugs. With further clinical research, the indications for Lynparza have gradually expanded and now cover a variety of cancer types. In addition, research also shows that olaparib is not only effective in patients with BRCA mutations, but may also be effective in other patients who carry specific DNA repair gene defects.